Researchers seeking Semax research peptide for sale require verified analytical purity, stringently documented sequence identity, and endotoxin-tested compounds. Semax is a synthetic heptapeptide derived from ACTH(4-10) widely investigated in preclinical models of neurotrophic signaling, BDNF expression, and cellular stress responses. PX1 Research supplies high-purity, US-manufactured Semax exclusively for laboratory research use only.
Researchers seeking Semax research peptide for sale require verified analytical purity, stringently documented sequence identity, and endotoxin-tested compounds. Semax is a synthetic heptapeptide derived from ACTH(4-10) widely investigated in preclinical models of neurotrophic signaling, BDNF expression, and cellular stress responses. PX1 Research supplies high-purity, US-manufactured Semax exclusively for laboratory research use only.
Semax is a synthetic heptapeptide featuring the primary amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was engineered as a stabilized analog of the adrenocorticotropic hormone fragment ACTH(4-10). Native ACTH fragments demonstrate distinct biological activity in neuro-regulatory assays, but naturally occurring sequences exhibit short enzymatic half-lives in biological fluids due to rapid cleavage by serum peptidases.
To address this bioanalytical limitation, structural modifications were introduced by appending a C-terminal Pro-Gly-Pro tripeptide motif to the core ACTH(4-10) sequence. This modification significantly enhances resistance to enzymatic degradation by carboxypeptidases and endopeptidases. In controlled laboratory environments, this enzymatic stability allows researchers to observe sustained molecular signaling without the rapid degradation typical of native neuropeptides. For detailed biochemical parameters, researchers can consult our detailed Semax research overview.
When procuring Semax for analytical assays, investigators must verify that the sequence is produced via solid-phase peptide synthesis (SPPS) and purified to prevent truncated sequences or residual synthesis reagents from confounding experimental outcomes.
A central focus of preclinical investigation involving Semax is its influence on neurotrophin expression, specifically Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). Preclinical studies suggest that administration of Semax in rodent models leads to a rapid and sustained upregulation of BDNF gene expression within the hippocampus and basal forebrain structures.
In vitro assays using primary neuronal cultures demonstrate that exposure to Semax triggers transcriptomic changes within hours. Researchers evaluating gene expression patterns via RT-qPCR have noted elevated mRNA levels for both BDNF and its high-affinity receptor, tropomyosin receptor kinase B (TrkB). This pathway plays a critical role in neuroplasticity, dendritic branching, and synaptic remodeling under baseline and challenge conditions.
Furthermore, neurotrophin stimulation observed in these models does not appear to operate through direct activation of classic adrenocortical steroid pathways. Because Semax lacks the full sequence necessary for steroidogenesis, preclinical data indicate that its cellular interactions proceed through independent neuro-modulatory signaling cascades. Review comprehensive literature and trial summaries in the PX1 Research library hub.
Beyond baseline neurotrophic expression, Semax has been extensively evaluated in animal models simulating acute cellular stress, hypoxia, and cerebral ischemia. In rodent paradigms involving transient middle cerebral artery occlusion (tMCAO), preclinical research demonstrates that Semax administration correlates with reduced volume of ischemic damage and preserved cellular integrity in surrounding penumbral tissue.
Mechanistic investigations into these stress responses reveal several overlapping pathways. First, in vitro data indicate that Semax modulates the gene expression profiles of key inflammatory cytokines, downregulating pro-inflammatory markers such as IL-6, TNF-alpha, and IL-1beta while maintaining anti-inflammatory signals. Second, the compound exhibits antioxidant properties, reducing lipid peroxidation and preserving superoxide dismutase (SOD) activity in neural cell homogenates under metabolic stress.
Additionally, transcriptomic profiling of brain tissues following ischemic challenge demonstrates that Semax modulates genes regulating vascular tone and extracellular matrix remodeling, including vascular endothelial growth factor (VEGF). These findings establish Semax as a versatile reference compound for laboratory investigations into neuroprotection, ischemic recovery mechanisms, and inflammatory modulation.
When designing preclinical protocols focusing on neuropeptides and regulatory signaling, researchers frequently contrast Semax with structural or functional analogs within the same synthetic class. The primary compounds evaluated alongside Semax include its modified derivatives and complementary regulatory sequences.
While Semax is derived from the ACTH(4-10) sequence and predominantly influences BDNF transcription and neurovascular signaling, Selank—an analog of the endogenous immunomodulatory peptide tuftsin—operates primarily through the modulation of GABAergic transmission and monoamine metabolism. Researchers comparing these compounds often utilize our Selank research guide to establish protocol parameters across neurotrophic versus anxiolytic preclinical models.
Modified analogs such as N-Acetyl Semax and N-Acetyl Semax Amidate feature chemical additions designed to further enhance lipophilicity and enzymatic resistance. Acylation at the N-terminus and amidation at the C-terminus alter the electrostatic charge of the peptide molecule, which can significantly modify membrane permeability and receptor binding kinetics in tissue culture assays. Selecting between standard Semax and acetylated variants depends on the specific pharmacokinetic and enzymatic parameters of the intended in vitro or ex vivo model.
In addition to neurotrophic factors, preclinical models show that Semax interacts with central monoaminergic systems. In rodent striatal slice preparations, application of Semax has been shown to alter dopamine and serotonin turn-over rates, promoting elevated extracellular concentrations of dopamine and its primary metabolites.
Electrophysiological studies on hippocampal slices indicate that exposure to Semax lowers the threshold for long-term potentiation (LTP) induction. LTP serves as the primary cellular model for learning and memory storage. By modulating both neurotrophic (BDNF/TrkB) and monoaminergic signaling, Semax provides a multi-target framework for researchers examining synaptic strength, receptor cross-talk, and cognitive processing paradigms in preclinical research models.
Importantly, preclinical data indicate that these monoaminergic shifts occur without inducing receptor desensitization or classical psychostimulation cascades, distinguishing ACTH-derived peptides from conventional synthetic neuromodulators.
Proper handling and preparation of lyophilized peptides are essential to maintain secondary structure and avoid experimental artifacts caused by degradation or aggregation. Semax is supplied as a sterile, lyophilized cake or powder that requires precise reconstitution prior to use in laboratory assays.
To reconstitute lyophilized Semax, researchers typically utilize sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl), depending on downstream cellular compatibility requirements. The diluent should be introduced down the inner wall of the glass vial rather than sprayed directly onto the peptide pellet to minimize shear stress and prevent foaming.
Gentle swirling should be applied until the solute is completely dissolved. Mechanical agitation, such as vigorous shaking or high-speed vortexing, should be strictly avoided as it can induce physical denaturation or cleavage of fragile peptide bonds. Once fully dissolved, solution aliquots should be prepared immediately to prevent repeated freeze-thaw cycles during subsequent analytical procedures.
Lyophilized Semax possesses high thermal stability when stored under controlled environment conditions. Unreconstituted vials should be stored at -20°C for short-to-medium term storage, or at -80°C for extended research timelines. Under these conditions, the peptide maintains structural stability and purity for up to 24 months from the date of synthesis.
Following reconstitution, liquid solutions exhibit greater susceptibility to hydrolytic and enzymatic degradation. Reconstituted Semax stored in sterile aqueous solutions should be maintained under refrigeration at 2°C to 8°C and utilized within 14 to 28 days if prepared with antimicrobial preservatives such as benzyl alcohol.
If pure sterile water is utilized without preservatives, solutions should be used immediately or frozen in single-use experimental aliquots at -80°C. Repeated freezing and thawing of liquid preparations accelerates aggregation and peptide breakdown, leading to variable concentrations in quantitative assays.
When procuring Semax research peptide for sale, establishing absolute analytical verification is critical. Laboratory findings can be severely compromised by batch-to-batch variability, residual TFA (trifluoroacetic acid) contamination, or presence of truncated peptide impurities generated during solid-phase synthesis.
A robust analytical verification standard requires lot-specific documentation, including:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Ensures purity levels exceed 98.0%, displaying clean peak retention times without structural degradation peaks.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular mass (theoretical molecular weight of 810.9 g/mol) to verify correct amino acid sequence identity.
3. Bacterial Endotoxin Testing: Measures endotoxin levels using the Limulus Amebocyte Lysate (LAL) assay, ensuring levels remain well below 0.1 EU/mg to prevent immune activation during cell culture assays.
PX1 Research provides comprehensive, lot-specific Certificates of Analysis (COAs) generated by independent ISO 17025 accredited laboratories with every shipment. Procurement teams can evaluate our complete catalog via our wholesale research accounts portal.
PX1 Research is dedicated exclusively to supporting the scientific community with chemical reagents that meet precise analytical criteria. All peptides available in our catalog are manufactured under strict Good Manufacturing Practice (GMP) compliant facilities within the United States.
Our supply chain architecture relies on domestic production and dual fulfillment centers located in California and Arizona. This infrastructure eliminates international customs delays, guaranteeing consistent batch availability and temperature-controlled storage prior to dispatch. Orders placed Monday through Friday before cut-off times qualify for same-day shipping.
Every batch of Semax offered for sale undergoes independent testing prior to release. By maintaining rigid quality control parameters, zero filler formulations, and full analytical transparency, PX1 Research serves as a dependable partner for academic institutions, biotechnology enterprises, and clinical research facilities. Explore our full range of compounds in our all peptides directory.
What is the primary target sequence of Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analog of the N-terminal fragment of adrenocorticotropic hormone, specifically ACTH(4-10), stabilized with a C-terminal tripeptide.
Is Semax approved for human consumption or clinical administration?
No. Semax provided by PX1 Research is strictly for laboratory research use only, in vitro cell culture, and preclinical animal models. It is not intended for human or veterinary use, medical diagnosis, treatment, or therapy.
What analytical standards are used to verify Semax purity?
PX1 Research verifies Semax purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity exceeding 98%, Mass Spectrometry (MS) to verify molecular weight, and LAL assays to ensure low endotoxin levels.
How should Semax be stored upon receipt?
Lyophilized Semax should be stored at -20°C or -80°C for long-term stability. Once reconstituted in sterile liquid media, solutions should be kept refrigerated between 2°C and 8°C and used within the timeframe determined by the specific preservative used.
What diluent is recommended for reconstituting Semax for laboratory assays?
For routine laboratory preparation, sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl) is typically utilized depending on the sensitivity of the specific cell line or analytical assay.
How does Semax differ structurally from native ACTH?
Semax contains only the ACTH(4-10) sequence linked to a C-terminal Pro-Gly-Pro fragment. This structural modification prevents rapid enzymatic degradation without triggering adrenocortical steroidogenesis associated with full-length ACTH.
Does PX1 Research provide lot-specific COAs with Semax orders?
Yes. Every lot of Semax shipped by PX1 Research includes a third-party Certificate of Analysis (COA) from an ISO 17025 accredited laboratory detailing HPLC purity, mass spectrum analysis, and endotoxin content.
Where is PX1 Research Semax manufactured and shipped from?
All PX1 Research peptides are synthesized in US-based, GMP-compliant facilities and shipped directly from our primary fulfillment centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.